166 related articles for article (PubMed ID: 3981803)
1. [Tissue polypeptide antigen in gynecological cancer].
Saitoh S; Nakanishi A; Noda T; Yoh S; Ando Y; Moriyama I; Ichijo M
Gan No Rinsho; 1985 Jan; 31(1):65-72. PubMed ID: 3981803
[TBL] [Abstract][Full Text] [Related]
2. [Clinical usefulness of serum TPA, IAP and CEA levels in gynecological cancer].
Saitoh S; Nakanishi A; Noda T; Ando Y; Kamamoto Y; Moriyama I; Ichijo M
Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1496-504. PubMed ID: 6520506
[No Abstract] [Full Text] [Related]
3. [A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies].
Nakajima H; Hirata T; Norisugi T; Furuno K; Ikehata N; Utsunomiya A; Kobayashi K; Negishi Y; Akiya K
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Oct; 36(10):1877-83. PubMed ID: 6094688
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies].
Ueda M; Sudo N; Furuya M; Arakawa O; Ikarashi T
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2361-8. PubMed ID: 3001201
[TBL] [Abstract][Full Text] [Related]
5. [A case of immunohistochemically carcinoembryonic antigen producing cervical cancer--the evaluation of plasma CEA levels in 201 patients with uterine cancer].
Yokoyama T; Kaneko H; Kawamura S; Tanaka M; Chiba T; Hiura M; Moriwaki S
Gan No Rinsho; 1987 Jul; 33(8):975-80. PubMed ID: 3613119
[TBL] [Abstract][Full Text] [Related]
6. Immuno-histological localization of tissue polypeptide antigen (TPA) in gynecological malignancies.
Ikarashi T; Takeuchi S; Sudo N; Ueda M; Furuya M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Oct; 37(10):2117-20. PubMed ID: 3908587
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of different serum tumor markers in gynecological malignancies.
Paulick R; Caffier H; Horner G; Lang K; Filbry E
Cancer Detect Prev; 1985; 8(1-2):115-20. PubMed ID: 4064031
[TBL] [Abstract][Full Text] [Related]
8. [The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor].
Inoue M; Inoue Y; Hiramatsu K; Tanaka Y; Yamasaki M; Ueda G; Minagawa J; Ozaki M; Yanagida T; Nishino H
Nihon Sanka Fujinka Gakkai Zasshi; 1984 May; 36(5):779-84. PubMed ID: 6736725
[TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
10. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
11. [An evaluation of carcinoembryonic antigen (CEA), beta 2-microglobulin (BMG), and immunosuppressive acidic protein (IAP) in the serum of primary lung cancer patients].
Higuchi Y
Gan No Rinsho; 1986 Jan; 32(1):33-40. PubMed ID: 3005690
[TBL] [Abstract][Full Text] [Related]
12. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
13. [Carcinoembryonic antigen in gynecological oncology].
Stiglmayer R
Fortschr Med; 1978 Oct; 96(37):1843-5. PubMed ID: 700565
[TBL] [Abstract][Full Text] [Related]
14. [Carcino-embryogenic antigen (CEA) in patients with genital tumors (author's transl)].
Anger H; Gleissenberger U
Geburtshilfe Frauenheilkd; 1977 Jul; 37(7):604-8. PubMed ID: 885332
[TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of CEA levels in lung cancer].
Noge S; Hara N; Ichinose Y; Ishimatsu T; Motohiro A; Etoh K; Miyake J; Ohta M
Gan No Rinsho; 1985 May; 31(6 Suppl):616-22. PubMed ID: 2993691
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of tissue polypeptide antigen in patients with esophageal, stomach and colon cancer].
Ogoshi K; Kondo Y; Akiba Y; Sugihara T; Ko S; Noto T; Makuuchi H; Tajima T; Mitomi T
Gan No Rinsho; 1984 Aug; 30(10):1299-302. PubMed ID: 6481966
[TBL] [Abstract][Full Text] [Related]
17. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas.
Sonoda K; Nakashima M; Kaku T; Kamura T; Nakano H; Watanabe T
Cancer; 1996 Apr; 77(8):1501-9. PubMed ID: 8608535
[TBL] [Abstract][Full Text] [Related]
18. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
20. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
